People don't quit Ozempic because it makes them sick

The 10s were not the lucky ones who escaped the side effects. They were the people watching the weight come off, and they would put up with almost anything to keep watching. Of the handful who said plainly that they meant to keep going, every one was still losing weight. Of the ones who meant to stop, nearly all were still sick. They were not leaving because the nausea had finally won. They were leaving because the scale had stopped moving.

I was not the only one to hear this. A 28-year-old woman with type 2 diabetes, quoted in a review of how patients describe these drugs, put it almost exactly: "As long as the weight comes off, I will put up with anything, as long as it goes." She even called her nausea "really good," because it kept her from eating. In a JAMA Network Open study published this year, patients described the same calculus in their own words. One described being "willing to live with" the side effects "because the results were so immediate and helpful."

The data the headlines lean on say it too, if you read them closely. The most repeated claim is that side effects are the number-one reason people stop. But that ranking is built from medical records, which can only capture reasons a clinician wrote down, and the everyday nausea people push through rarely makes it into the chart. One of the largest real-world studies of these drugs found what the headlines skipped: the more weight a person lost, the less likely they were to quit, and after they stopped, the more weight they regained, the more likely they were to start again. People who responded came back. The pooled trial data are blunter still. The famous nausea lasts, on average, only about a week. And the gut side effects overall are mild or moderate ninety-eight percent of the time, driving barely four in a hundred people off the drug for good. The weight loss, the trials found, happens largely independently of them. Which is the whole point:

The sickness was never doing the work, and it was never the exit.

None of this means side effects do not matter. A few people are genuinely flattened by these drugs, and severe reactions do push some of them out, which the same records confirm. And when people say the drug "stopped working," they usually mean they hit a plateau, which is the body settling at a new, lower weight, not the drug giving up. But that is a reason to walk people through the plateau, not to assume they left because they could not stomach it.

Here is why the wrong story is dangerous. The cost argument over these drugs is essentially settled. Independent analysts have judged them cost-effective by the usual American standard. Having lost on price, payers have retreated to a new objection, which is that people do not stay on them. Half of the insurers that decline to cover these drugs for obesity now say no price would change their minds, with the high rate at which people stop the drugs driving the decision. From 2025 to 2026, twelve million Americans were on health plans that dropped Wegovy, and twelve million more on plans that dropped Zepbound.

But if people stay when the drug works and leave when it does not, then most of that discontinuation is not waste. It is the system doing exactly what it should, stopping a drug in the people it is not helping. The real waste runs the other way. It is dropping coverage on the people it is helping, the early responders, who then regain the weight and, the records show, come back to start over. Sean Scanlon, Connecticut's state comptroller, defended tying his state's coverage to a weight-management program by saying that if a patient keeps eating fast food and does not exercise, "then we're just basically wasting money." But he is watching the wrong patient. The drug is not wasted on the person it fails. That person quits, and the bill stops with them. It is wasted when a rule like his drives out the person it is meant to serve.

Gordon made a real choice, and a defensible one. Not everyone belongs on these drugs, and feeling healthy is not the same as being thin. But she is not the typical patient, and we have built an entire policy around the people who leave. The typical patient is the one still at the reception, quietly nauseated, watching the weight go, willing to put up with anything as long as it keeps going. We are about to decide whether she gets to keep the one thing that has worked. We should at least get the reason right.